Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 18 小时前评分70
正文 · 机器翻译
#ESMO26 🧬 Epsametostat (HH2853) | II期
🎯 晚期上皮样肉瘤
💊 EZH1/2双重抑制剂
👥 94例患者 | 75例可评估疗效
📈 ORR: 40% | DCR: 77.3%
⏳ mPFS: 13.1个月 | mDoR: 15.6个月
🎯 mOS: 未达到
⚠️ G≥3 TRAEs: 39.4%
🚀 主要终点达到！
52 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com